B
Biosion
Global clinical-stage biotechnology company developing antibody-based therapies for immune and oncologic diseases
About Biosion
Biosion is a global clinical-stage biotechnology company developing innovative antibody-based therapies for patients with immune and oncologic diseases. Established in 2017, the company builds its pipeline on internally developed proprietary platforms, including the H3 antibody discovery platform, the SynTracer HT endocytosis screening platform and the Flexibody bispecific antibody platform. Its pipeline spans monoclonal antibodies, bispecific antibodies and antibody-drug conjugates, with lead candidate bosakitug (BSI-045B, an anti-TSLP monoclonal antibody) in late-stage clinical development for inflammatory and allergic disease.
The company operates a discover-development-partnership model and has established ten global collaborations, advancing nine clinical-stage assets across immunology and oncology. Partners include Aclaris Therapeutics, which secured an exclusive global license to two Biosion immunology assets in 2024, and Celldex Therapeutics, which develops CDX-585, a bispecific antibody from a research collaboration with Biosion. Biosion is headquartered in Nanjing, China, with US corporate operations in Newark, Delaware, and activities across the United States, China and Australia.
Revenue is primarily generated through research and development collaborations, licensing agreements and future commercial sales of its biologics.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Nanjing City, China
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 69.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2023 | $2.8M | $138M | Hangzhou Ruiying Asset · Hemeng Venture Capital | ↗ |
| SERIES B✓Equity / VC | Dec 2022 | $14M | $138M | Su xin Venture Capital · Yida Capital · Fang Fund Partners · GF Xinde Investment | ↗ |
Growth signals
Latest recorded traffic for Biosion is 300 monthly website visits, down 61% over the last three months. Biosion's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
3E Bioventures- SCSu xin Venture Capital
- YCYida Capital
Fang Fund Partners- GIGF Xinde Investment
- HAHangzhou Ruiying Asset
- HCHemeng Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biosion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biosion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.